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Summary
 
T cell line–tropic (T-tropic) HIV type 1 strains enter cells by interacting with the cell-surface
molecules CD4 and CXCR4. We have generated transgenic mice predominantly expressing
human CD4 and CXCR4 on their CD4-positive T lymphocytes (CD4
 
1
 
 T cells). Their pri-
mary thymocytes are susceptible to T-tropic but not to macrophage-tropic HIV-1 infection in
vitro, albeit with a viral antigen production less efficient than human peripheral blood mono-
nuclear cells. Interestingly, even without HIV infection, transgenic mice display a CD4
 
1
 
 T cell
depletion profile of peripheral blood reminiscent of that seen in AIDS patients. We demon-
strate that CD4
 
1
 
 T cell trafficking in transgenic mice is biased toward bone marrow essentially
due to CXCR4 overexpression, resulting in the severe loss of CD4
 
1
 
 T cells from circulating
blood. Our data suggest that CXCR4 plays an important role in lymphocyte trafficking
through tissues, especially between peripheral blood and bone marrow, participating in the reg-
ulation of lymphocyte homeostasis in these compartments. Based on these findings, we propose
a hypothetical model in which the dual function of CXCR4 in HIV-1 infection and in lym-
phocyte trafficking may cooperatively induce progressive HIV-1 infection and CD4
 
1
 
 T cell
decline in patients.
 
H
 
uman immunodeficiency virus 1 (HIV-1) has been
broadly categorized into three groups: macrophage-
tropic (M-tropic)
 
1
 
 nonsyncytium-inducing, T cell line–
tropic (T-tropic) syncytium-inducing, and dual tropic mixed
phenotypes (1–4). Primary isolates from early asymptom-
atic HIV-1 infection are frequently M-tropic, suggesting
that M-tropic HIV-1 strains play a critical role in establish-
ing infection (1–6). During the clinical course, T-tropic
strains emerge at a later stage associated with a decline in
CD4 positive T lymphocytes (CD4
 
1
 
 T cells), suggesting
that these strains may be related to AIDS pathogenesis (1–6).
To enter cells, M- and T-tropic strains use distinct G
protein–coupled seven-transmembrane chemokine recep-
tors in addition to their common receptor, human CD4
(4–6). M-tropic strains use receptors for CC-chemokines,
including RANTES (regulated on activation, normal T cell
expressed and secreted), macrophage inflammatory protein
(MIP)-1
 
a
 
, and MIP-1
 
b
 
 
 
(7, 8),
 
 
 
or
 
 
 
other chemokine recep-
tor–like orphan receptors (9, 10).
 
 
 
T-tropic strains, in con-
trast, mainly use CXCR4 (11, 12), the receptor for CXC-
chemokine stromal cell–derived factor 1 (SDF-1) (13, 14).
These chemokines function as chemotactic factors for he-
matopoietic lineage cells, including granulocytes, mono-
cytes, lymphocytes, and their progenitor cells (7, 8, 15). It
has been suggested that these chemokines play roles in the
migration of these cells to local inflammation sites and in
their homing to distant organs during development. The
function and regulation of expression of these chemokine
receptors may underlie the mechanisms of HIV transmis-
sion, latency, and immunodeficiency.
 Although these chemokine receptors have been shown
to facilitate HIV entry into cell lines, it remains unknown
whether they are able to render mouse primary lympho-
cytes susceptible to HIV infection. Transgenic mice whose
 
1
 
Abbreviations used in this paper:
 
 CD4 (and CD8) SP, CD4 (and CD8) sin-
gle positive; h, human; m, murine; M-tropic, macrophage-tropic; MIP,
macrophage inflammatory protein; RANTES, regulated on activation,
normal T cell expressed and secreted; SDF-1, stromal cell–derived factor 1;
T-tropic, T cell line–tropic.
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Transgenic Mice Expressing T-tropic HIV-1 Receptors
 
CD4
 
1
 
 T cells have HIV infectability are expected to prove
useful as a small-animal model for developing therapeutic
reagents against HIV infection and for understanding the
basis of AIDS pathogenesis. Here we report the generation
of transgenic mice that predominantly express human CD4
and CXCR4 on their CD4
 
1
 
 T cells and CD4
 
1
 
 thy-
mocytes. Thymocytes from transgenic mice were found to
be susceptible to T- but not M-tropic HIV-1 infection in
vitro. Interestingly, the tissue distribution of CD4
 
1
 
 T cells
in these mice was deregulated with the severe loss of CD4
 
1
 
T cells from peripheral blood coinciding with their accu-
mulation in bone marrow, and this was shown to be essen-
tially a result of CXCR4 overexpression. Our data suggest
that CXCR4 plays an important role both in the regulation
of lymphocyte trafficking and in T-tropic HIV-1 infection
of primary lymphocytes and may provide insights into the
pathogenesis of CD4
 
1
 
 T cell decline in AIDS patients.
 
Materials and Methods
 
Production of Transgenic Mice.
 
The human CXCR4 (hCXCR4)
cDNA was obtained by PCR from the human PBL cDNA li-
brary (Human Peripheral Blood Leukocyte Quick-Clone
 
Ô
 
;
Clontech, Palo Alto, CA) using the following primers: primer 1,
5
 
9
 
-TGAGTCGACTGAGTGCTCCAGTAGCCACC; primer
2, 5
 
9
 
-TAGGTCGACAGATCTTGTACAATATTGGTCAGT-
CTT. PCR was done using cloned PFU DNA polymerase (Strat-
agene Inc., La Jolla, CA) for 30 cycles each consisting of 1 min at
94
 
8
 
C, 1 min at 55
 
8
 
C, and 3 min 72
 
8
 
C. The cDNA product was
digested with SalI restriction endonuclease and inserted into the
SalI site of the mouse CD4 transgene designed for restricted ex-
pression of a transgene in CD4
 
1
 
 T cells (16). The 40-kb genomic
fragment containing all exons as well as 5
 
9
 
 and 3
 
9
 
 region of the
human CD4 (hCD4) gene was joined with the murine CD4 en-
hancer (17). These two transgenes were separated from the vec-
tors on an agarose gel, purified, and coinjected into the nuclei of
mouse oocytes of (B6D2)F1 mice. Transgenic founders were
screened for the expression of hCD4 and hCXCR4 in their PBLs
by FACS
 
Ò
 
 (Becton Dickinson and Co., Mountain View, CA)
analysis, as well as for the integration of transgenes (hCD4 and
hCXCR4) in their genomic DNA by PCR analysis. The
founders were mated with C57BL/6J mice to generate the prog-
eny. Mice are maintained in the SPF facility (Department of Ex-
perimental Animal Research, RIKEN).
 
Cell Culture and Infection Assays.
 
Human PBMCs purified with
the lymphosepar I buffer (IBL, Fujioka, Japan) and mouse thy-
mocytes passed through a nylon mesh were washed with PBS,
and then cultured at 5 
 
3 
 
10
 
5
 
 (PBMCs) and 5 
 
3 
 
10
 
6
 
 (thymocytes)
cells/ml
 
 
 
in RPMI complete medium containing 3 
 
m
 
g/ml PHA
(Sigma Chemical Co., St. Louis, MO) and 4 ng/ml
 
 
 
recombinant
human IL-2 (PeproTech EC, London, UK) or murine IL-2
(R&D Systems, Inc., Minneapolis, MN). On day 2, cells were
harvested, counted, and 10
 
6
 
 (human PBMCs) or 5 
 
3 
 
10
 
6
 
 (murine
thymocytes) cells were inoculated with the medium (1 ml) con-
taining HIV-1 viruses (5 ng of p24 antigen) at 37
 
8
 
C for 3 h in the
presence of 5 
 
m
 
g/ml
 
 
 
polybrene (Sigma Chemical Co.). After
washing three times with PBS, cells were treated with trypsin
(0.025%) EDTA (0.27 mM) (GIBCO BRL, Gaithersburg, MD)
for 3 min at 37
 
8
 
C, and then washed with complete medium three
times. Cells were cultured in the presence of human or murine
IL-2 (4 ng/ml). IL-2 was added to the culture medium every 2 d.
On indicated days after infection, the supernatant (200 
 
m
 
l) was re-
moved for a p24 enzyme immunoassay (Abbott, Abbott Park, IL). 
 
Construction of SDF-1-C
 
g
 
1. 
 
A cDNA clone encoding mu-
rine SDF-1
 
a
 
 was cloned into pBluescript SK (
 
2
 
) (Stratagene Inc., La
Jolla, CA) (18). The 3
 
9
 
 end of the coding sequences of mSDF-1
 
a
 
was mutated to delete the stop codon and to introduce an EcoRI
site by PCR using the following primers: sense primer 5
 
9
 
-CCT-
CGAGGTCGACGGTATCGATA-3
 
9
 
 and antisense primer 5
 
9
 
-
ATGGACCTCTTTCGAAATTTGTTCCCTTAAGCC-3
 
9
 
. Af-
ter EcoRI digestion, the PCR product of expected size (310 bp)
was subcloned into a pC
 
g
 
1/Bluescript SK (
 
2
 
) vector containing
human IgG1 constant region genomic sequences (provided by H.
Yagita, Juntendo University School of Medicine, Tokyo, Japan)
(19). Clones with mSDF-1
 
a
 
 gene in right direction were chosen.
The procedure resulted in an in-frame fusion gene between
mSDF-1
 
a
 
 and huC
 
g
 
1(SDF-1–C
 
g
 
1). After confirming the se-
quences, a 1.7-kb XhoI–NotI fragment was subcloned into pBC-
MGSneo expression vector (20). A pSDF-1-C
 
g
 
1/BCMGSneo
vector was transfected into Ag 8.653 B cell tumors using Lipofec-
tin (GIBCO BRL) and stable transfectants were established after
G418 selection.
 
Flow Cytometry Analysis.
 
FACS
 
Ò
 
 analysis was performed on
FACSort (Becton Dickinson and Co.). Peripheral blood from
mice was incubated in red blood cell lysis buffer and washed with
PBS, and 10
 
5
 
 cells were stained with monoclonal antibodies on
ice for 30 min in PBS containing FCS (5%) and the Fc block
(PharMingen, San Diego, CA) for hCXCR4 staining, or normal
mouse serum (10%) for hCD4 staining. For anti–hCXCR4 stain-
ing, anti–mouse IgG2a-FITC was used as the secondary antibody.
After washing with PBS, cells were analyzed on a FACSort. For
SDF-1–C
 
g
 
1 staining, cells were preincubated with 10% goat se-
rum plus the Fc block. Cells were incubated with SDF-1–C
 
g
 
1 at
4
 
8
 
C for 40 min, washed once, and further reacted with FITC
anti–huIgG goat (Fab
 
9
 
)
 
2
 
 antibody (Cappel, Aurora, Ohio). The
monoclonal antibodies used in this study are as follows: rat anti–
mouse CD4(L3T4)-PE (PharMingen), rat anti–mouse CD8
(Ly2)-TRICOLOR (Caltag Laboratories, Burlingame, CA), rat
anti–mouse IgG2a-FITC (PharMingen), rat anti–mouse CD16/
CD32 (Fc block; PharMingen), mouse anti–hCXCR4 (12G5)
(provided by J.A. Hoxie, University of Pennsylvania, Philadelphia,
PA), mouse anti–hCD4-FITC (Dako SA, Glostrup, Denmark). 
 
PCR Amplification of HIV Proviral DNA.
 
Thymocytes infected
with HIV strains in vitro as described above were harvested on
day 2 after infection. Genomic DNA was extracted from these
cells (21). PCR was performed with primers (LTR5: 5
 
9
 
-GGC-
TAACTAGGGAACCCACTGCTT-3
 
9
 
, and LTR6: 5
 
9
 
-CTG-
CTAGAGATTTTCCACACTGAC-3
 
9
 
) for the early product of
proviral DNA, or primers (LTR5 and 5NC2: 5
 
9
 
-CCGAGTC-
CTGCGTCGAGAGAGC-3
 
9
 
) for its late product (22), in com-
bination with the IL-1 primers (5
 
9
 
-CTCTAGAGCACCATGC-
TACAGAC-3
 
9
 
, and 5
 
9
 
-TGGAATCCAGGGGAAACACTG-3
 
9
 
)
of the murine IL-1 gene, which served as a control. Reactions
were done in 50 
 
m
 
l of reaction mixture for 35 cycles. Southern
hybridization was performed with the oligo nucleotide probes,
LTR9 (5
 
9
 
-GCCTCAATAAAGCTTGCCTTG-3
 
9
 
) for HIV DNA
and mIL-1 (5
 
9
 
-TGTAAGAATACCCAGACAGCTTTAAGGA-
TGGGAGGG-3
 
9
 
) for the IL-1 gene, labeled with digoxigenin-
ddUTP, and detection was performed using a DIG luminescent
detection system (Boehringer Mannheim, Mannheim, Germany).
 
Chemotaxis Assay.
 
Chemotaxis assays for murine and human
lymphocytes were performed as previously described (23). In brief,
murine splenic mononuclear cells purified with lymphosepar II
(IBL), or human PBMCs purified with lymphosepar I (IBL) were 
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washed three times with PBS, resuspended in RPMI containing
0.25% BSA, and 10
 
6
 
 cells in 100 
 
m
 
l were added to the top cham-
bers of 50-
 
m
 
m–pore polycarbonate Transwell (Costar Corp.,
Cambridge, MA). For pretreatment of lymphocytes with pertussis
toxin, cells were incubated with complete medium containing
pertussis toxin (100 ng/ml) or medium alone for 2 h at 37
 
8
 
C un-
der 5% CO
 
2
 
, and were then washed twice with PBS. Human
SDF-1
 
a
 
 (PeproTech, Inc., Rocky Hill, NJ) was added to the
lower chambers containing 600 
 
m
 
l 0.25% BSA RPMI medium.
In control experiments, other chemokines such as murine MIP-1
 
a
 
(Sigma Chemical Co.), murine monocyte chemoattractant pro-
tein (MCP)-1 (PharMingen), murine MCP-5 (PeproTech, Inc.),
or human RANTES (85% amino acid sequence homology with
murine RANTES; R&D Systems Inc.) were added to the lower
chambers. After a 3-h incubation at 37
 
8
 
C with 5% CO
 
2
 
, the cells
that migrated into the lower chambers were harvested and
counted with a FACSort for 30 s at high speed, gating on the for-
ward and side scatter of the lymphocytes. For murine spleen cells
and human PBMCs, the input cells and the migrated cells were
stained with antibodies for CD4 and CD8 and analyzed on FAC-
Sort to evaluate the migration activity of each T cell subset.
 
In Vivo Migration Assays.
 
Donor lymphocytes were prepared
from the spleen and the peritoneal lymph node of mice that were
either doubly transgenic for hCD4 and hCXCR4 or singly trans-
genic for hCD4. The lymphocytes (5–9 
 
3 
 
106) were injected in
the tail vein of normal mice (BDF1) (24). After 3 or 16 h, the re-
cipient mice were killed, cells from their tissues were stained with
anti–hCD4 FITC, anti–mCD4 PE, and anti–mCD8 TRICOLOR,
and the cells were analyzed by three-color flow cytometry.
Results
Targeted Human CD4 and CXCR4 Expression in Mouse
CD41 T Cells. Two transgenes containing either hCD4
genomic DNA or hCXCR4 cDNA were constructed un-
der the control of CD4 gene cis elements to express them
specifically in CD41 T cells (16, 17). These constructs were
comicroinjected into the nuclei of fertilized murine oo-
cytes. Of transgenic offspring, mouse No. 12 displayed the
highest level of both hCD4 and hCXCR4 expression in T
lymphocytes. Both transgenes were cotransmitted to all
transgene-positive progeny of this mouse, indicating that
the two constructs were stably integrated into the same
chromosome. Mouse No. 12’s progeny were therefore an-
alyzed in detail.
In FACSÒ profiles of their lymphocytes, human CD4
and hCXCR4 were coexpressed in the CD4 subset, but
not in the CD8 subset, of peripheral T lymphocytes (Fig. 1,
A and B). Both molecules were also detected specifically on
CD41CD81 (double positive) and CD41CD82 thymocytes
of transgenic mice (Fig. 1, C and D, and data not shown).
Human CD4, but not hCXCR4, was also detected in
monocytes, B lymphocytes, and NK cells of transgenic
mice, albeit at lower levels (data not shown). The hCD4
expression level in transgenic peripheral CD41 T cells was
higher than that seen in human PBLs. The hCXCR4 ex-
pression level (mean fluorescence intensity [MFI]: 12.44)
was also higher than that seen in unstimulated human PBLs
(MFI: 4.13), but lower than that in human PBLs stimulated
by PHA and IL-2 (MFI: 20.19). Since SDF-1 is a natural
ligand for CXCR4, SDF-1 binding assays were performed
for transgenic and nontransgenic T lymphocytes using mu-
rine SDF-1a–huCg1 fusion protein. Murine SDF-1a
(mSDF-1a) is 98.6% identical to human SDF-1a (hSDF-
1a) in its predicted amino acid sequences and is thought to
interact with hCXCR4 (13, 25). Murine SDF-1a binding
activity was significantly higher in transgenic CD4 single
positive (SP) T lymphocytes and double positive thy-
mocytes, but not in CD8 SP T lymphocytes, in line with
the hCXCR4 expression pattern in transgenic mice (Fig. 1
E and data not shown). This result indicates that total re-
ceptors for murine SDF-1, including endogenous CXCR4
and hCXCR4, are overexpressed specifically in CD41 T
lymphocytes of transgenic mice. The level of SDF-1 recep-
tor expression in transgenic CD41 T cells (MFI; 76.82) was
in the physiological range observed in control mouse CD41
T cell blasts activated with PHA (5 mg/ml), Con A (2 mg/ml),
and mIL-2 (5 ng/ml) for 1 d in vitro (MFI; 138.06). The
levels of SDF-1 receptor in normal mouse thymocytes and
peripheral T lymphocytes will be published elsewhere (Su-
zuki, G., Y. Nakata, Y. Dan, A. Uzawa, K. Nakagawa, T.
Sato, K. Mita, and T. Shirasawa, manuscript in preparation). 
HIV Infection In Vitro. Although several chemokine re-
ceptors have been shown to facilitate HIV entry into cell
lines, it remains to be determined whether they are able to
render mouse primary immune cells susceptible to HIV in-
fection. We therefore studied the susceptibility of trans-
genic lymphocytes to HIV-1 infection in vitro. Transgenic
thymocytes express hCXCR4 at a higher level than pe-
ripheral lymphocytes (Fig. 1, B and D), so we used them
for in vitro HIV infection. HIV gag p24 antigen produc-
tion was clearly detected in the culture supernatant of
transgenic thymocytes exposed to T-tropic strains IIIB and
SF2, showing a time course more rapid than that of human
PBMCs (Fig. 2 A). The p24 level produced by transgenic
thymocytes was significantly lower, however, than that
produced by human PBMCs after 4 d of infection. Barriers
to efficient HIV replication may therefore still exist in
transgenic mouse thymocytes (26), or, alternatively, this
may reflect the poor viability of mouse thymocytes at this
stage of culturing. In contrast, M-tropic HIV-1 strain
SF162 neither allowed control nor transgenic thymocytes
to produce the p24 antigen, in line with previous observa-
tions that M-tropic strains use different chemokine recep-
tor classes to enter cells (5, 6, 9, 10). Genomic DNA from
mouse thymocytes was subjected to PCR amplification us-
ing HIV primers. Both early- and late-stage products were
detected specifically in DNA isolated from transgenic thy-
mocytes exposed to the T-tropic HIV-1 strain (Fig. 2 B).
Compared with thymocytes, lower levels of p24 antigens
were detected in the culture supernatants of spleen lym-
phocytes exposed to T-tropic HIV strains (data not
shown). This may be due, at least in part, to their lower
hCXCR4 expression compared with that in thymocytes.
Abnormal Tissue Distribution of CD4 SP T Lymphocytes.
Interestingly, transgenic mice had significantly lower CD4
SP (CD41CD82) T cell counts in peripheral blood (Fig. 3,
A and B). CD8 SP (CD42CD81) T cell counts were also1442 Transgenic Mice Expressing T-tropic HIV-1 Receptors
slightly reduced, but reduction varied with the individual
mouse (data not shown). In contrast, the proportion and
number of CD4 SP T cells in the thymus, and especially in
bone marrow, were elevated (Fig. 3, A and B). Since bone
marrow contains immature CD4 positive cells, three-color
analysis was conducted using antibodies against murine
CD3, CD4, and CD8. The number of mature CD3-posi-
tive CD4 SP T cells increased significantly in the bone
marrow of transgenic mice (Fig. 3 B). Both the lymph
nodes and spleen maintained relatively higher percentages
of CD4 SP T cells than did peripheral blood (Fig. 3 B).
These findings suggest that CD4 SP T cell reduction in
peripheral blood was due to neither reduced production in
the thymus nor elimination from peripheral tissues, but was
due, rather, to abnormal distribution in tissue compart-
ments. Other double transgenic mouse lines expressing
hCD4 and undetectable levels of hCXCR4 in peripheral
CD4 SP T cells showed normal CD4 SP T cell counts in
Figure 1. (A–D) hCD4 and
hCXCR4 are expressed predomi-
nantly on CD41 subsets of PBLs and
thymocytes in transgenic mice. Three-
color flow cytometric analysis of hCD4
and hCXCR4 expression on PBLs (A
and B) and thymocytes (C and D) of a
control nontransgenic mouse (Non-Tg)
and of a transgenic litter mate (Tg).
Cells were stained with FITC-conju-
gated monoclonal antibody against
hCD4 (A and C) or hCXCR4 (B and
D) in the presence of monoclonal an-
tibodies against murine CD4 (PE) and
CD8 (TRICOLOR). (E) Three-color
analysis of receptors for murine SDF-1
(open histograms) on gated CD41CD82
(CD4 SP) and CD42CD81 (CD8 SP)
subsets of lymph node T cells from
control and transgenic littermates.
Background levels obtained with the
FITC anti–huIgG alone are shown in
solid histograms. 1443 Sawada et al.
peripheral blood (data not shown). Human CD4 expres-
sion alone at high levels in CD4 SP T cells in hCD4 single
transgenic mice did not reduce the number of these cells in
peripheral blood (data not shown; see references 17 and
27). Moreover, the administration of pertussis toxin, a spe-
cific G protein blocker, to transgenic mice predominantly
increased the CD4 subset in blood, and, reciprocally, de-
creased levels observed in bone marrow (Fig. 3, C and D).
These results suggest that signaling through hCXCR4,
rather than through hCD4, is critical in developing this
phenotype.
Augmented Chemotactic Response to SDF-1. It was recently
found that SDF-1, the natural ligand for CXCR4, func-
tions as a potent chemoattractant for murine and human T
lymphocytes in vitro, and for murine lymphocytes in vivo
(23, 28). In vitro chemotaxis assay demonstrated that trans-
genic CD4 SP T cells, but not CD8 SP T cells, were more
hyperresponsive to SDF-1 than were nontransgenic cells,
indicating that hCXCR4 expression in CD4 SP T cells in-
creases their responsiveness to SDF-1 (Fig. 4 A). They
were even more sensitive to SDF-1 than human CD4 SP T
cells, which may be explained by the hCXCR4 expression
level in transgenic CD4 SP T cells, which is higher than
that of unstimulated human PBLs. Cell migration was
eliminated by pretreatment with pertussis toxin, indicating
that G-protein participates in signaling through CXCR4,
similar to other seven-transmembrane receptors (Fig. 4 B).
The response of CD4 SP T cells to several other lympho-
cyte chemoattractants was, however, similar between trans-
genic and nontransgenic mice (Table 1).
Based on these in vivo and in vitro findings, it is tempt-
ing to speculate that large numbers of transgenic CD4 SP T
cells migrate and become trapped in mouse tissues, such as
bone marrow (29), whose stromal cells produce high levels
of SDF-1, resulting in the loss of circulating CD4 SP T
cells from the blood. It is important to note that the pre-
dicted amino acid sequences of both SDF-1 and CXCR4
are highly conserved between the human and mouse, and
that murine SDF-1 induces signals through human CXCR4
(13, 25, 30, and see Discussion).
Biased Migration of Transgenic CD41 T Cells. We analyzed
the in vivo migration of transgenic CD41 T cells in cell
transfer experiments. Peripheral lymphocytes of transgenic
mice were injected intravenously into normal mice. Those
of another transgenic mouse line, which expressed hCD4
but not hCXCR4 on its CD4 subset of T cells, were also
injected into mice as controls. 3 or 16 h after injection, hu-
man CD4-positive murine CD41CD82 T lymphocytes in
tissues of recipient mice were analyzed and counted using
three-color flow cytometry (Fig. 5, A and B). The number
of circulating double transgenic CD4 SP T cells in periph-
eral blood was significantly lower than that of single trans-
genic CD4 SP T cells. In contrast, double transgenic CD4
SP T cell migration to bone marrow was higher than that
of single transgenic control CD4 SP T cells. This discrep-
ancy appeared increasingly pronounced when tissues were
analyzed 16 h after cell transfer. Both transgenic CD4 SP T
cells migrated to the spleen in similar numbers (data not
shown). These results are compatible with the tissue distri-
bution of CD4 SP T cells seen in double transgenic mice,
and support the notion that the expression of hCXCR4 al-
tered CD4 SP T cell homeostasis in blood by enhancing
their migration to specific tissues, such as bone marrow. 
Discussion
In this study, we analyzed transgenic mice coexpressing
human CD4 and CXCR4 predominantly in their CD41 T
cells. The expression of these molecules facilitated the in-
fection of mouse primary thymocytes with T-tropic strains
of HIV-1 in vitro. Transgenic mice also displayed severe
CD41 T cell depletion in peripheral blood, with a con-
comitant increase of these cells in bone marrow. We dem-
onstrated that trafficking of transgenic CD41 T cells was
biased toward bone marrow, inducing the CD41 T cell loss
from the blood pool. This phenotype has not been ob-
served in transgenic mouse lines expressing hCD4 alone
and was normalized transiently upon administration of a
specific G-protein inhibitor, pertussis toxin. These findings
Figure 2. T-tropic HIV in-
fection in transgenic thy-
mocytes. (A) PHA-stimulated
thymocytes from 6-wk-old
control nontransgenic mice,
transgenic mice, or human PB-
MCs were exposed to T-tropic
HIV strains IIIB and SF2, or an
M-tropic SF162 for 3 h. After
washing three times with PBS,
cells were treated with trypsin-
EDTA for 3 min, and then
washed three times with com-
plete medium. The p24 antigen
was assayed in the medium immediately after cell washing (day 0) and in the culture supernatant harvested on the indicated days after infection. Back-
ground levels taken to be those on day 0 were subtracted from the amount of p24. Results shown are the mean 6 SD of duplicated infections. (B) PCR
amplification of HIV DNA in control or transgenic thymocytes infected with IIIB or SF162. Murine IL-1 gene primers were used for internal control.
The product with LTR5/LTR6 represents the early HIV DNA product, whereas that with LTR5/5NC2 represents the late product (22). Anticipated
DNA size is as follows: 139 bp (LTR5/LTR6), 202 bp (LTR5/5NC2), 308 bp (IL-1). Similar results were obtained in two independent experiments (A
and B). 1444 Transgenic Mice Expressing T-tropic HIV-1 Receptors
Figure 3. Abnormal CD41 T cell distribution in transgenic mice and transient normal distribution recovery after an injection of pertussis toxin. (A)
Flow cytometric analysis of lymphocytes in tissues from 5-wk-old nontransgenic (left) and transgenic (right) litter mates. (B) Percentage of CD4 SP T cells
in lymphoid cells from tissues of 5-wk-old litter mates (n 5 9). CD31 CD4 SP T cells are shown for bone marrow because it contained immature CD32
CD41 cells. Bone marrow cells gated on lymphoid cells may include immature myeloid and erythroid lineage cells. Data is the averaged value obtained1445 Sawada et al.
and in vivo cell migration analysis indicated that signaling
through hCXCR4 was a primary factor in developing this
phenotype. 
T-tropic HIV-1 Susceptibility of Transgenic Mouse Thymocytes.
The simultaneous expression of hCD4 and hCXCR4 in
mouse CD4 T lymphocytes removed the restriction of
HIV-1 infection in these cells to some extent. The level of
p24 antigens, however, was significantly lower than that
produced by human PBMCs after 4–6 d of infection (Fig. 2
A). This suggests that additional cellular factors are required
to efficiently replicate viruses in mouse lymphocytes and
presumably for the generalized HIV-1 infection in mice. It
has been reported, for example, that cellular elements re-
quired for Tat and Rev functions during postentry HIV life
cycle processes are lacking in mouse cell lines (26). Unlike
T-tropic strains, M-tropic strain SF162 was shown to be
noninfectious for transgenic thymocytes, which agrees with
previous observations that M-tropic strains use different
classes of chemokine receptors to enter cells (5, 6, 9, 10).
Human CD4 expression alone in mice does not confer
sensitivity to T-tropic HIV-1 infection (31). The T-tropic
HIV-1 sensitivity of hCD41 single transgenic thymocytes
was similar to that of nontransgenic thymocytes in our ex-
periments (data not shown). Human CXCR4 expression,
therefore, appears to be required for susceptibility, and
structural differences in CXCR4 between the human and
mouse may critically affect virus entry in primary T lym-
phocytes. However, rodent CXCR4 expression in nonper-
missive hCD41 cell lines has been shown to render these
cells susceptible to T-tropic HIV-1 (32–34). Since the
quantity of SDF-1 receptors was significantly higher in
CD41 T cells of double transgenic mice than in controls
(Fig. 1 E), it is alternatively possible that the CXCR4
quantity expressed on the cell surface, irrespective of the
species, may determine HIV-1 susceptibility and that en-
dogenous CXCR4 levels expressed in lymphocytes from
hCD4 single transgenic mice are not high enough for sus-
ceptibility.
Role of CXCR4 in Lymphocyte Trafficking and Homeostasis.
Lymphocyte migration through tissues is thought to in-
volve various surface molecules such as adhesion molecules
and chemokine receptors at multiple steps, and its physio-
logical regulation appears complex (35, 36). CXCR4 mole-
cules are expressed on hematopoietic cells such as lymphocytes
and monocytes (28). Although mRNA of SDF-1, a natural
ligand for CXCR4, can be detected in lymphoid and non-
lymphoid tissues, its expression in bone marrow stromal
cells is especially high (29). Since SDF-1 can function as a
potent chemoattractant for lymphocytes (23) and hemato-
poietic progenitor cells (37), it has been proposed that it
plays a role in lymphocyte trafficking through tissues for
immune surveillance (23, 28) and in the homing of he-
matopoietic progenitor cells to bone marrow microenvi-
ronments (37). In SDF-1 null mice, hematolymphopoiesis
Figure 4. Hyperresponse of transgenic CD41 T cells to SDF-1 in a
chemotaxis assay. (A) Spleen mononuclear cells from nontransgenic and
transgenic mice or from human PBLs were analyzed for migration toward
the SDF-1 gradient. The percentage of migrated CD4 SP or CD8 SP T
cells to input cells of each subset was calculated (Materials and Methods).
(B) SDF-1-induced chemotaxis of murine CD4 SP T cells was eliminated
with pertussis toxin. After 2 h pretreatment with medium or pertussis
toxin (100 ng/ml), chemotaxis of lymphocyte subsets in response to SDF-1
(40 ng/ml) was analyzed. Results (A and B) are the mean 6 SD of dupli-
cated experiments. Similar results were obtained in two independent ex-
periments (A and B). 
Table 1. Chemotaxis of Murine Spleen CD4 T Lymphocytes to 
Different Chemokines
Chemokines (ng/ml)
Migrated CD4 T cells
(percentage of input CD4 T cells)
Non-Tg Tg
SDF-1a (100) 16.6 6 2.9 63.5 6 2.1
mMIP-1a (10) 3.2 6 0.1 3.1 6 0.3
mMCP-1 (30) 4.2 6 0.3 3.8 6 0.1
mMCP-5 (50) 4.1 6 0.2 3.1 6 0.6
hRANTES (100) 4.2 6 0.4 3.3 6 0.5
Medium alone 2.5 6 0.3 2.4 6 0.0
Spleen mononuclear cells from nontransgenic and transgenic mice were
tested for in vitro migration toward active chemokine concentrations.
Input and migrated cells were counted and stained with antibodies for
CD4 and CD8 to evaluate CD4 SP T cell migration activity. Results
are the mean 6 SD of duplicate experiments.
with three nontransgenic and six transgenic mice. The averaged number of lymphoid cells in each tissue is as follows: peripheral blood, 9.78 3 106/ml
(Non-Tg) vs. 9.38 3 106/ml (Tg); thymus, 1.97 3 108 vs. 1.45 3 108; bone marrow, 2.52 3 107 vs. 1.95 3 107; spleen, 6. 07 3 107 vs. 3.71 3 107;
lymph node, 7.27 3 107 vs. 6.15 3 107. PB, peripheral blood; LN, lymph node; BM, bone marrow. (C) Before and after intraperitoneal injection of per-
tussis toxin (500 ng) or control saline, murine peripheral blood was analyzed using a flow cytometer on indicated days. The percentage of CD4 SP T cells
in blood lymphocytes is shown. Data represents mean values obtained with two mice for each experimental set. Similar results were obtained in two in-
dependent experiments. (D) 5 d after injection of pertussis toxin (500 ng) or control saline i.p., mice were analyzed for CD31 CD4 SP T cell counts in
blood and bone marrow (two femurs). Data is mean values 6 SD obtained with two mice. PT, pertussis toxin. Similar results were obtained in three in-
dependent experiments. 1446 Transgenic Mice Expressing T-tropic HIV-1 Receptors
was abolished in bone marrow but not in fetal liver, consis-
tent with the proposed role for the SDF-1/CXCR4 path-
way in hematopoietic cell development (38). Since these
mice die perinatally, however, the in vivo role of SDF-1
for lymphocytes in adult mice has not been clarified.
The primary structures of murine and human SDF-1 are
identical except for a single amino acid change of Ile to Val
at position 18 (13), and mSDF-1 induces signals through
hCXCR4 and vice versa (13, 25). CXCR4 is also highly
conserved between the mouse and human, especially in its
transmembrane and cytoplasmic amino acid sequences
(96% identical) (30). Transgenic CD41 T cells that express
hCXCR4 showed, in fact, significantly higher mSDF-1
binding activity than those of controls (Fig. 1 E), indicating
that transgenic mice overexpress receptors for endogenous
SDF-1, specifically in their CD41 T cells. This is compati-
ble with the functional analysis showing that CD4, but not
CD8, SP T cells of transgenic mice had a heightened
chemotactic response to SDF-1 (Fig. 4). These mice thus
provide an SDF-1 receptor-overexpression model for clari-
fying the in vivo role of the SDF-1/CXCR4 pathway in
lymphocyte lineage cells. SDF-1 binding activity of trans-
genic CD41 T cells was in a physiological range similar to
the upregulated level in nontransgenic T cells upon in vitro
activation. 
Our findings on transgenic mice are summarized as fol-
lows: (a) CD4 SP T cell depletion in peripheral blood ac-
companying their accumulation in bone marrow (Fig. 3, A
and B); (b) transient normalization of this abnormal CD4
SP T cell distribution upon administration of a G-protein
blocker, pertussis toxin (Fig. 3, C and D); and (c) preferen-
tial migration of hCD41hCXCR41 double transgenic
CD4 SP T cells toward bone marrow and their rapid disap-
pearance from peripheral blood, compared with hCD41
single transgenic CD4 SP T cells, in cell transfer experi-
ments (Fig. 5). These findings suggest that the CXCR4
pathway participates in lymphocyte trafficking through tis-
sues and, specifically, may play a key role in lymphocyte
circulation between peripheral blood and bone marrow
whose stromal cells produce high levels of SDF-1 (29). It
Figure 5. In vivo migration of transgenic CD41 T cells. 9 3 106 (A) or
5 3 106 (B) lymphocytes from two transgenic mice lines expressing either
hCD4 alone (hCXCR42) or both hCD4 and hCXCR4 (hCXCR41)
were injected intravenously into normal BDF1 mice. The proportions of
hCD41, mCD41, and mCD82 in each lymphocyte preparation were
similar (16–23%). Values are mean numbers (6SD) of recovered hCD41,
mCD41, and mCD82 donor T cells in peripheral blood (per 1 ml) or
bone marrow (per two femurs) of recipient mice 3 (A) or 16 (B) h after
injection. Two (A) and five (B) mice were used for each cell transfer.
*P , 0.05, **P , 0.01, and ***P , 0.0001 determined by Student’s t test.
Similar results were obtained in three independent experiments.
Figure 6. Models for the CXCR4 role in lymphocyte trafficking and in AIDS pathogenesis. (A) CXCR4high lymphocytes such as activated lympho-
cytes (28) preferentially migrate to bone marrow or other tissues/microenvironments whose stromal cells produce high levels of SDF-1 (29). CXCR4 ex-
pression regulation may thus involve lymphocyte trafficking between peripheral blood and bone marrow, influencing lymphocyte homeostasis in these
compartments. (B) In transgenic mice, hCXCR4 is constitutively expressed on CD41 T cells, and SDF-1 receptors are overexpressed in these cells (see
text). CD41 T cells are therefore trapped in bone marrow, resulting in their loss from peripheral blood. (C) Model for the CD41 T cell decline in AIDS
patients. When active HIV-1 replication loci are present in bone marrow (42, 43), T-tropic HIV-1 infection accelerates because of preferential recruit-
ment of CXCR4 high lymphocytes to bone marrow. Migrated CXCR4high CD41 T cells are destroyed after HIV-1 infection and do not return to the
blood pool. Note that the trafficking balance of CD41 T cells through bone marrow mimics that in transgenic mice in B.1447 Sawada et al.
has been shown that CXCR4 expression in T lymphocytes
is regulated by activation (28). The regulation of CXCR4
expression may therefore modulate lymphocyte trafficking
between the blood pool and bone marrow reservoir (39,
40), influencing lymphocyte homeostasis in these compart-
ments under physiological and pathological conditions such
as viral infection and autoimmune diseases (Fig. 6 A). In
our transgenic mice, such homeostasis appears to be specif-
ically disrupted in CD4 SP T cells that constitutively ex-
press hCXCR4 (Fig. 6 B). 
Other molecule(s) involved in cell migration rather than
CXCR4 may play a role in developing the transgenic
mouse phenotype. Forced CXCR4 expression, for exam-
ple, would modulate other pertussis-toxin-sensitive chemo-
kine receptors that actually induce the phenotype. The in
vitro chemotaxis of transgenic CD4 SP T cells to several
lymphocyte chemoattractants other than SDF-1, however,
did not significantly differ from that of nontransgenic CD4
SP T cells (Table 1), favoring the possibility that signaling
through hCXCR4 upon binding endogenous SDF-1
changed the CD4 SP T cell distribution in transgenic mice.
Hypothetical AIDS Pathogenesis Model. The resemblance
of blood lymphocyte profiles of transgenic mice and AIDS
patients prompts us to surmise a link between CXCR4
function and AIDS pathogenesis. CXCR4high lymphocytes
(e.g., activated lymphocytes; reference 28), are expected to
migrate preferentially to bone marrow, as suggested by our
transgenic mice, and presumably to other tissues or mi-
croenvironments that produce critical SDF-1 levels. The
CXCR4 expression level appears correlated with T-tropic
HIV-1 infectability (41). When bone marrow contains ac-
tive HIV replication loci (42, 43), such a milieu may pro-
vide selective pressure to accumulate viruses that use CXCR4
for cell entry, and would accelerate T-tropic HIV-1 infec-
tion by recruiting susceptible CXCR4high CD41 T cells.
This would lead to a severe CD41 T cell trafficking imbal-
ance in the bone marrow compartment, where infected
cells would be destroyed and unable to return to the blood
pool, and the situation would eventually resemble that re-
sulting from “trapping” in the bone marrow of transgenic
mice (Fig. 6 C). Such an absorption of CD41 T cells from
circulating blood may also finally drain peripheral lym-
phoid organs.
Clinical observations that HIV-1 infection and activity
in bone marrow correlate with CD4 cell depletion in pro-
gressive stages (43–45) appear to support this hypothesis.
According to this view, the recovery of CD41 T cell ho-
meostasis in the peripheral blood of patients after potent
anti–HIV therapy (46) could be due, at least in part, to an
improved trafficking imbalance. Observations that SDF-1
inhibits T-tropic HIV-1 replication in vitro (13, 14, 41)
may contradict this model. It is conceivable, however, that
SDF-1 gradients in bone marrow microenvironments gen-
erate local regions displaying levels that enable T-tropic
HIV-1 to replicate. It has been shown that the concentra-
tion of SDF-1 required to inhibit HIV-1 infection appears
to be significantly higher than that required for receptor
signaling or binding (47). Many CXCR4 using primary
HIV-1 isolates were also shown to be resistant to SDF-1-medi-
ated suppression of PBMC infection in contrast to labora-
tory-adapted, T cell line-tropic strains (48). The analysis of
in situ SDF-1 expression, CXCR4 expression in lympho-
cyte subsets, and the status of HIV replication in tissues, in-
cluding bone marrow, during HIV-1 infection may there-
fore help further our understanding of AIDS pathogenesis. 
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